ClinicalTrials.gg
Sign In

Leukemia, B-Cell clinical trials

The registry lists 190 studies for Leukemia, B-Cell across more than 10 countries. 52 are recruiting or about to start. 81 of them are mainly about Leukemia, B-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Leukemia, Lymphocytic, Chronic, B-Cell too: 2,164 studies, 274 open.

Get an email when these change. Save the Leukemia, B-Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
62
Recruiting
39
Status unknown
31
Active, not recruiting
19
Terminated
19
Not yet recruiting
12

Phase

Phase 1
85
Phase 2
84
Phase 3
12
Early Phase 1
8
Phase 4
3

Where

United States
79
China
46
United Kingdom
28
Germany
21
Italy
21
Spain
17

Who runs them

GlaxoSmithKline (7) · AstraZeneca (7) · German CLL Study Group (6) · National Heart, Lung, and Blood Institute (NHLBI) (6) · Pharmacyclics LLC. (4) · Baylor College of Medicine (4) · National Cancer Institute (NCI) (4) · Novartis Pharmaceuticals (4)

What is being tested here

Drugs under test in Leukemia, B-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pirtobrutinib313
Zanubrutinib203
Surovatamig212
Cyclophosphamide107
Acalabrutinib115
Lenalidomide105
ARQ531102
Epcoritamab101
PKC-beta Inhibitor MS-553101
Anti-CD19/CD3 Bispecific Antibody MK-1045101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 8 open · Alkylating agents 1 open · Antimitotic agents 3

Coming up

5phase 3 studies under way
19studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 39 Leukemia, B-Cell studies recruiting now, 18 (46%) set no upper age limit and 16 (41%) stop at 75 or younger. 16 (41%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (3%) take healthy volunteers.

Recruiting studies that take each age, of 39
AgeWomenMen
1014 (36%)14 (36%)
1839 (100%)39 (100%)
3033 (85%)33 (85%)
4032 (82%)32 (82%)
5032 (82%)32 (82%)
6532 (82%)32 (82%)
7530 (77%)30 (77%)
8522 (56%)22 (56%)

Across all 190 studies, recruiting or not: 34% stop at 75 or younger and 14% at 65; 36% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, B-Cell studies take

Of 32 phase 1 interventional studies under Leukemia, B-Cell, half reached primary completion within 61 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 161 mo33–119 · 32 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting2

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 190. Browse all 190 → or search them.